The protocol at a glance
There is no human dose. Rodent studies gave it by mouth, but those amounts cannot be turned into a safe human dose.
| Item | What the sources show |
|---|---|
| Human dose | Not established |
| Studied in | Rats and mice (given by mouth) |
Oral dosing in rodents is described in Benoist 2014 and the 2021 Alzheimer's mouse study. ClinicalTrials.gov lists no Dihexa trial (searched 5 Nov 2026).
Community notes report 5 to 30 mg a day by mouth. There is no human study behind this.
What people say they do, collected from community discussions. Not tested in a trial; shown so you can compare it with the evidence above.
Mixing
No mixing table here: this one is used as a capsule, nasal spray or skin product, or has no human amount to calculate from. The general mixing calculator works for any vial.
What the trials found
No human results exist. Animal evidence only:
Benoist CC et al. J Pharmacol Exp Ther 2014 (PMID 25187433); Brain Sci 2021 (PMID 34827486).
Side effects
- No human safety data exists.
How it works
HGF / c-Met pathway
Dihexa binds hepatocyte growth factor (HGF) and boosts its c-Met signal. It grew new synapses in rat brain cells.
PI3K/AKT pathway
In Alzheimer's-model mice it switched on PI3K/AKT signaling and lowered brain inflammation markers.
Sources
- Benoist CC et al. J Pharmacol Exp Ther 2014, PMID 25187433
- AngIV-analog Dihexa in APP/PS1 mice. Brain Sci 2021, PMID 34827486
- ClinicalTrials.gov search by intervention name, run 5 Nov 2026: 0 results